TABLE 1. Demographic characteristics of COVID-19 vaccine recipients and unvaccinated comparison group — seven integrated health care organizations, United States, December 14, 2020–July 31, 2021.
| Characteristic | No. (%) |
||||
|---|---|---|---|---|---|
| mRNA vaccine* |
Janssen vaccine |
||||
| Pfizer-BioNTech vaccine recipients | Moderna vaccine recipients | Unvaccinated comparison group†,§ | Janssen vaccine recipients | Unvaccinated comparison group† | |
|
Total
|
3,452,126 (100.0)
|
2,604,066 (100.0)
|
3,243,112 (100.0)
|
342,169 (100.0)
|
1,346,445 (100.0)
|
|
Age group, yrs
| |||||
| 12–17 |
316,587 (9.2) |
NA |
311,445 (9.6) |
NA |
NA |
| 18–44 |
1,322,147 (38.3) |
951,899 (36.6) |
1,153,735 (35.6) |
141,317 (41.3) |
558,996 (41.5) |
| 45–64 |
1,072,819 (31.1) |
913,075 (35.1) |
987,703 (30.5) |
158,157 (46.2) |
624,106 (46.4) |
| 65–74 |
440,879 (12.8) |
454,391 (17.4) |
468,679 (14.5) |
28,721 (8.4) |
109,143 (8.1) |
| 75–84 |
219,888 (6.4) |
216,968 (8.3) |
233,870 (7.2) |
9,835 (2.9) |
37,745 (2.8) |
| ≥85 |
79,806 (2.3) |
67,733 (2.6) |
87,680 (2.7) |
4,139 (1.2) |
16,455 (1.2) |
|
Sex
| |||||
| Male |
1,586,867 (46.0) |
1,185,265 (45.5) |
1,395,196 (43.0) |
177,867 (52.0) |
696,190 (51.7) |
| Female |
1,865,259 (54.0) |
1,418,801 (54.5) |
1,847,916 (57.0) |
164,302 (48.0) |
650,255 (48.3) |
|
Race/Ethnicity
| |||||
| Hispanic |
738,931 (21.4) |
600,654 (23.1) |
871,863 (26.9) |
69,602 (20.3) |
329,921 (24.5) |
| White, non-Hispanic |
1,472,716 (42.7) |
1,151,826 (44.2) |
1,397,345 (43.1) |
154,188 (45.1) |
585,489 (43.5) |
| Asian, non-Hispanic |
573,754 (16.6) |
369,069 (14.2) |
432,782 (13.3) |
45,909 (13.4) |
200,430 (14.9) |
| Black, non-Hispanic |
175,066 (5.1) |
145,127 (5.6) |
189,592 (5.8) |
20,996 (6.1) |
73,174 (5.4) |
| Multiple races/Other/Unknown | 491,659 (14.2) | 337,390 (13.0) | 351,530 (10.8) | 51,474 (15.0) | 157,431 (11.7) |
Abbreviations: Janssen = Johnson & Johnson; NA = not applicable.
* Among Pfizer-BioNTech COVID-19 vaccine recipients, 2,980,152 received the second dose by May 31, 2021; among Moderna COVID-19 vaccine recipients, 2,362,157 received the second dose by May 31, 2021.
† Unvaccinated comparison group included unvaccinated persons and COVID-19 vaccine recipients before COVID-19 vaccination. The assignment of index dates allowed COVID-19 vaccinees to contribute unvaccinated person-time before vaccination, thus avoiding immortal time bias.
§ mRNA vaccines included Pfizer-BioNTech and Moderna COVID-19 vaccines.